SCHEDULE: Decheng Capital Boosts BeyondSpring Stake to 11.2%
Beneficial Ownership Report
Decheng Capital and its affiliates, led by Xiangmin Cui, have reported an 11.2% beneficial ownership stake in BeyondSpring Inc. as of June 30, 2025.
Summary
- Decheng Capital Management III (Cayman), LLC and Decheng Capital China Life Sciences USD Fund III, L.P. each beneficially own 1,979,072 ordinary shares, representing 4.9% of BeyondSpring Inc.'s class.
- Decheng Capital Management II (Cayman), LLC and Decheng Capital China Life Sciences USD Fund II, L.P. each beneficially own 1,617,409 ordinary shares, representing 4.0% of the class.
- Decheng Capital Global Healthcare Fund (Master), LP and Decheng Capital Global Healthcare GP, LLC each beneficially own 935,000 ordinary shares, representing 2.3% of the class.
- Xiangmin Cui, as the sole manager of Decheng Capital Management II and III, and indirect managing member of Decheng Capital Global Healthcare GP, LLC, beneficially owns an aggregate of 4,531,481 ordinary shares, representing 11.2% of the class.
- The reported percentages are based on 40,316,320 ordinary shares outstanding as of April 30, 2025, as reported in BeyondSpring Inc.'s Form 10-Q filed on May 12, 2025.
Sentiment
Score: 5
Explanation: The filing is a factual report of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or prospects.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor in a publicly traded biotechnology company. It reflects an investment position rather than operational or strategic updates, which are typically found in other types of SEC filings.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2025-04-30 | Date as of which 40,316,320 ordinary shares were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-05-12 | Date BeyondSpring Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2025-06-30 | Date of event which requires filing of this statement, representing the reporting period end date for beneficial ownership. |
| 2025-08-14 | Date the Schedule 13G/A Amendment No. 2 was signed and filed. |
Keywords
BeyondSpring Inc., Decheng Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals, Investment, Shareholder, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.